Clinical trials: Epirubicin
Breast Cancer
Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP
This study is a single-arm, single-center exploratory clinical study. Twenty patients with early-stage HER2-positive breast cancer are planned to be included, and the primary objective is to evaluate the efficacy of neoadjuvant…
- Trial name
- NCT04929548
- Testing
- Pyrotinib Maleate Tablets
- Volunteers
- 20 people
- Sponsor
- Wuhan University
Nasopharyngeal Carcinoma
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China and Southeast Asia.
- Trial name
- NCT02363400
- Testing
- MEP
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- National Health Research Institutes, Taiwan
Breast Cancer
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
This is an open randomized phase III study. The primary objective of this study is to compare FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated according to the patients surface area or…
- Trial name
- NCT03888677
- Testing
- 5-FU, epirubicin and cyclophosphamide
- Volunteers
- 1,535 people
- Sponsor
- Henrik Lindman
Breast Adenocarcinoma
Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
The goal of this clinical trial is to compare the efficacy and safety in patients with lymph node-positive HR+/HER2- breast cancer.
- Trial name
- NEOTRIO-HR (NCT06671262)
- Testing
- SBRT, Immuno-chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
TNBC, Adjuvant Therapy
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer.
- Conditions
- TNBC, Adjuvant Therapy, Lymph Node Positive
- Trial name
- NCT07622836
- Testing
- Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer
- Trial name
- SOFIA (NCT00548899)
- Testing
- Nexavar (Sorafenib)
- Where
- 9 sites in Germany
- Volunteers
- 36 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen…
- Trial name
- NCT01301040
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Triple-negative Breast Cancer
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR)…
- Conditions
- Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
- Trial name
- NCT04138719
- Testing
- Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Epirubicin
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Hebei Medical University Fourth Hospital
Unilateral HER2 Positive Breast Cancer
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy
Anthracycline/taxane based combination chemotherapy of at least 18 weeks represents the standard of care in the neoadjuvant setting. In HER2 positive disease trastuzumab is given simultaneously.
- Trial name
- DAFNE (NCT01594177)
- Testing
- Afatinib, Trastuzumab, Paclitaxel
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- GBG Forschungs GmbH
Breast Neoplasms
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way.
- Trial name
- NCT01740271
- Testing
- Epirubicin
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- AHS Cancer Control Alberta
Esophageal Neoplasms
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial
The purpose of this study is to compare the results of preoperative chemotherapy and radiation followed by surgery to surgery followed by postoperative chemotherapy and radiation for esophageal cancer.
- Trial name
- QUINTETT (NCT00907543)
- Testing
- Preoperative treatment of chemotherapy and radiation, Postoperative treatment of chemotherapy and radiation
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- Richard Malthaner
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve…
- Trial name
- PEONY (NCT02586025)
- Testing
- FEC Chemotherapy, Surgery, Docetaxel
- Where
- 23 sites in China, South Korea and 2 more
- Volunteers
- 329 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
This study aims to evaluate the efficacy and safety of pyrotinib in combination with nab-paclitaxel or trastuzumab with nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2-positive breast cancer.
- Trial name
- NCT04066790
- Testing
- Pyrotinib, nab-Paclitaxel, Trastuzumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advanced HCC(IM brave 150).
- Trial name
- NCT06199297
- Testing
- Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells following…
- Trial name
- NCT00047099
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 2 sites in Germany
- Volunteers
- 446 people
- Sponsor
- Ludwig-Maximilians - University of Munich
CYP3A Phenotyping, CYP3A5 and MDR1 Genotyping
Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Twenty patients with verified high risk breast cancer will be included in the study. Patients will receive three cycles of docetaxel followed by three cycles of CEF for their adjuvant treatment.
- Conditions
- CYP3A Phenotyping, CYP3A5 and MDR1 Genotyping, Docetaxel Toxicity, Associations Between Genetic Data and Docetaxel Toxicity
- Trial name
- Docetaxel (NCT01110291)
- Testing
- docetaxel + CEF
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- University of Turku
Carcinoma of Urinary Bladder, Superficial
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
The aim of the study is to test the value of immediate post-operative intravesical instillation of epirubicin in patients with intermediate and high risk non muscle invasive bladder cancer (NMIBC).
- Trial name
- NMIBCIVT (NCT02214602)
- Testing
- Epirubicin
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Mansoura University
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Primary Breast Cancer
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
We aimed to evaluate the noninferiority of short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or short-term anthracycline-based chemotherapy (CEF-T, three cycles of…
- Trial name
- NCT01314833
- Testing
- Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel
- Where
- China
- Volunteers
- 1,570 people
- Sponsor
- Fudan University
Breast Cancer, Triple Negative Breast Neoplasms
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
This is a multicenter, prospective, randomized, open-label phase II study evaluating the efficacy and safety of PO→EC as neoadjuvant treatment of operable and locally advanced breast cancer in patients with HR deficiency.
- Conditions
- Breast Cancer, Triple Negative Breast Neoplasms, HRpos Breast Neoplasms, BRCA 1 /2 and / or HRD
- Trial name
- GeparOla (NCT02789332)
- Testing
- PwO, PwCb, EC
- Where
- 12 sites in Germany
- Volunteers
- 107 people
- Sponsor
- GBG Forschungs GmbH